Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Effective delivery of a microtubule polymerization inhibitor synergizes with standard regimens in models of pancreatic ductal adenocarcinoma.

Eberle-Singh JA, Sagalovskiy I, Maurer HC, Sastra SA, Palermo CF, Decker AR, Kim MJ, Sheedy J, Mollin A, Cao L, Hu J, Branstrom A, Weetal M, Olive KP.

Clin Cancer Res. 2019 Jun 7. pii: clincanres.3281.2018. doi: 10.1158/1078-0432.CCR-18-3281. [Epub ahead of print]

PMID:
31175095
2.

Modeling Pancreatic Cancer through Somatic Editing with AAV.

Curiel-GarcÍa A, Olive KP.

Trends Mol Med. 2019 May;25(5):361-362. doi: 10.1016/j.molmed.2019.02.012. Epub 2019 Mar 13.

PMID:
30878400
3.

Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes.

Maurer C, Holmstrom SR, He J, Laise P, Su T, Ahmed A, Hibshoosh H, Chabot JA, Oberstein PE, Sepulveda AR, Genkinger JM, Zhang J, Iuga AC, Bansal M, Califano A, Olive KP.

Gut. 2019 Jun;68(6):1034-1043. doi: 10.1136/gutjnl-2018-317706. Epub 2019 Jan 18.

PMID:
30658994
4.

Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition.

Abdalla MY, Ahmad IM, Rachagani S, Banerjee K, Thompson CM, Maurer HC, Olive KP, Bailey KL, Britigan BE, Kumar S.

Transl Res. 2019 May;207:56-69. doi: 10.1016/j.trsl.2018.12.008. Epub 2019 Jan 4.

PMID:
30653942
5.

β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer.

Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes Z, Maurer HC, Chen X, Jiang Z, Westphalen CB, Ilmer M, Valenti G, Mohanta SK, Habenicht AJR, Middelhoff M, Chu T, Nagar K, Tailor Y, Casadei R, Di Marco M, Kleespies A, Friedman RA, Remotti H, Reichert M, Worthley DL, Neumann J, Werner J, Iuga AC, Olive KP, Wang TC.

Cancer Cell. 2018 Nov 12;34(5):863-867. doi: 10.1016/j.ccell.2018.10.010. No abstract available.

6.

Laser Capture Microdissection on Frozen Sections for Extraction of High-Quality Nucleic Acids.

Maurer HC, Olive KP.

Methods Mol Biol. 2019;1882:253-259. doi: 10.1007/978-1-4939-8879-2_23.

PMID:
30378061
7.

Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness.

Renz BW, Tanaka T, Sunagawa M, Takahashi R, Jiang Z, Macchini M, Dantes Z, Valenti G, White RA, Middelhoff MA, Ilmer M, Oberstein PE, Angele MK, Deng H, Hayakawa Y, Westphalen CB, Werner J, Remotti H, Reichert M, Tailor YH, Nagar K, Friedman RA, Iuga AC, Olive KP, Wang TC.

Cancer Discov. 2018 Nov;8(11):1458-1473. doi: 10.1158/2159-8290.CD-18-0046. Epub 2018 Sep 5.

PMID:
30185628
8.

Technical Note: In vivo Young's modulus mapping of pancreatic ductal adenocarcinoma during HIFU ablation using harmonic motion elastography (HME).

Nabavizadeh A, Payen T, Saharkhiz N, McGarry M, Olive KP, Konofagou EE.

Med Phys. 2018 Nov;45(11):5244-5250. doi: 10.1002/mp.13170. Epub 2018 Oct 1.

PMID:
30178474
9.

Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma.

Arnes L, Liu Z, Wang J, Maurer C, Sagalovskiy I, Sanchez-Martin M, Bommakanti N, Garofalo DC, Balderes DA, Sussel L, Olive KP, Rabadan R.

Gut. 2018 Feb 10. pii: gutjnl-2017-314353. doi: 10.1136/gutjnl-2017-314353. [Epub ahead of print] Erratum in: Gut. 2019 May;68(5):952.

PMID:
29440233
10.

β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer.

Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes Z, Maurer HC, Chen X, Jiang Z, Westphalen CB, Ilmer M, Valenti G, Mohanta SK, Habenicht AJR, Middelhoff M, Chu T, Nagar K, Tailor Y, Casadei R, Di Marco M, Kleespies A, Friedman RA, Remotti H, Reichert M, Worthley DL, Neumann J, Werner J, Iuga AC, Olive KP, Wang TC.

Cancer Cell. 2018 Jan 8;33(1):75-90.e7. doi: 10.1016/j.ccell.2017.11.007. Epub 2017 Dec 14. Erratum in: Cancer Cell. 2018 Nov 12;34(5):863-867.

11.

Current and Emerging Therapies in Metastatic Pancreatic Cancer.

Manji GA, Olive KP, Saenger YM, Oberstein P.

Clin Cancer Res. 2017 Apr 1;23(7):1670-1678. doi: 10.1158/1078-0432.CCR-16-2319. Review.

12.

Fanning the Flames of Cancer Chemoresistance: Inflammation and Anticancer Therapy.

Olive KP.

J Oncol Pract. 2017 Mar;13(3):181-183. doi: 10.1200/JOP.2017.021154. No abstract available.

13.

Multivalent Small-Molecule Pan-RAS Inhibitors.

Welsch ME, Kaplan A, Chambers JM, Stokes ME, Bos PH, Zask A, Zhang Y, Sanchez-Martin M, Badgley MA, Huang CS, Tran TH, Akkiraju H, Brown LM, Nandakumar R, Cremers S, Yang WS, Tong L, Olive KP, Ferrando A, Stockwell BR.

Cell. 2017 Feb 23;168(5):878-889.e29. doi: 10.1016/j.cell.2017.02.006.

14.

Pancreatic Cancer: Progress and Challenges in a Rapidly Moving Field.

Collisson EA, Olive KP.

Cancer Res. 2017 Mar 1;77(5):1060-1062. doi: 10.1158/0008-5472.CAN-16-2452. Epub 2017 Feb 16.

15.

Elasticity mapping of murine abdominal organs in vivo using harmonic motion imaging (HMI).

Payen T, Palermo CF, Sastra SA, Chen H, Han Y, Olive KP, Konofagou EE.

Phys Med Biol. 2016 Aug 7;61(15):5741-54. doi: 10.1088/0031-9155/61/15/5741. Epub 2016 Jul 12.

16.

Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis.

Westphalen CB, Takemoto Y, Tanaka T, Macchini M, Jiang Z, Renz BW, Chen X, Ormanns S, Nagar K, Tailor Y, May R, Cho Y, Asfaha S, Worthley DL, Hayakawa Y, Urbanska AM, Quante M, Reichert M, Broyde J, Subramaniam PS, Remotti H, Su GH, Rustgi AK, Friedman RA, Honig B, Califano A, Houchen CW, Olive KP, Wang TC.

Cell Stem Cell. 2016 Apr 7;18(4):441-55. doi: 10.1016/j.stem.2016.03.016.

17.

Harmonic motion imaging for abdominal tumor detection and high-intensity focused ultrasound ablation monitoring: an in vivo feasibility study in a transgenic mouse model of pancreatic cancer.

Chen H, Hou GY, Han Y, Payen T, Palermo CF, Olive KP, Konofagou EE.

IEEE Trans Ultrason Ferroelectr Freq Control. 2015 Sep;62(9):1662-73. doi: 10.1109/TUFFC.2015.007113.

18.

Stroma, Stroma Everywhere (Far More Than You Think).

Olive KP.

Clin Cancer Res. 2015 Aug 1;21(15):3366-8. doi: 10.1158/1078-0432.CCR-15-0416. Epub 2015 May 15.

19.

Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism.

Bednar F, Schofield HK, Collins MA, Yan W, Zhang Y, Shyam N, Eberle JA, Almada LL, Olive KP, Bardeesy N, Fernandez-Zapico ME, Nakada D, Simeone DM, Morrison SJ, Pasca di Magliano M.

Carcinogenesis. 2015 Jul;36(7):730-8. doi: 10.1093/carcin/bgv058. Epub 2015 May 4.

20.

Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.

Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O'Connor OA.

Clin Cancer Res. 2015 May 1;21(9):2096-106. doi: 10.1158/1078-0432.CCR-14-2249. Epub 2015 Feb 12.

21.

Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging.

Harmsen S, Huang R, Wall MA, Karabeber H, Samii JM, Spaliviero M, White JR, Monette S, O'Connor R, Pitter KL, Sastra SA, Saborowski M, Holland EC, Singer S, Olive KP, Lowe SW, Blasberg RG, Kircher MF.

Sci Transl Med. 2015 Jan 21;7(271):271ra7. doi: 10.1126/scitranslmed.3010633.

22.

Protein breakdown precedes pancreatic tumor development.

Holmstrom SR, Olive KP.

Nat Med. 2014 Oct;20(10):1097-9. doi: 10.1038/nm.3714. No abstract available.

PMID:
25295937
23.

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ.

Cancer Cell. 2014 Jun 16;25(6):735-47. doi: 10.1016/j.ccr.2014.04.021. Epub 2014 May 22.

24.

Translational therapeutics in genetically engineered mouse models of cancer.

Olive KP, Politi K.

Cold Spring Harb Protoc. 2014 Feb 1;2014(2):131-43. doi: 10.1101/pdb.top069997.

PMID:
24492770
25.

Acquisition of mouse tumor biopsies through abdominal laparotomy.

Sastra SA, Olive KP.

Cold Spring Harb Protoc. 2014 Jan 1;2014(1):47-56. doi: 10.1101/pdb.prot077834.

26.

Identification and manipulation of biliary metaplasia in pancreatic tumors.

Delgiorno KE, Hall JC, Takeuchi KK, Pan FC, Halbrook CJ, Washington MK, Olive KP, Spence JR, Sipos B, Wright CV, Wells JM, Crawford HC.

Gastroenterology. 2014 Jan;146(1):233-44.e5. doi: 10.1053/j.gastro.2013.08.053. Epub 2013 Aug 30.

27.

Pancreatic cancer: why is it so hard to treat?

Oberstein PE, Olive KP.

Therap Adv Gastroenterol. 2013 Jul;6(4):321-37. doi: 10.1177/1756283X13478680.

28.

Recapitulating human cancer in a mouse.

Chin L, de Sauvage F, Egeblad M, Olive KP, Tuveson D, Weiss W.

Nat Biotechnol. 2013 May;31(5):392-5. doi: 10.1038/nbt.2575. No abstract available.

PMID:
23657389
29.

Quantification of murine pancreatic tumors by high-resolution ultrasound.

Sastra SA, Olive KP.

Methods Mol Biol. 2013;980:249-66. doi: 10.1007/978-1-62703-287-2_13.

30.

Genetically engineered mouse models of pancreatic cancer.

Westphalen CB, Olive KP.

Cancer J. 2012 Nov-Dec;18(6):502-10. doi: 10.1097/PPO.0b013e31827ab4c4. Review.

31.

Silencing the killers: paracrine immune suppression in pancreatic cancer.

Cox AD, Olive KP.

Cancer Cell. 2012 Jun 12;21(6):715-6. doi: 10.1016/j.ccr.2012.05.029.

32.

A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.

Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1243-53. doi: 10.1007/s00280-011-1613-0. Epub 2011 Mar 23.

33.

Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.

Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR.

Cancer Cell. 2010 Nov 16;18(5):499-509. doi: 10.1016/j.ccr.2010.10.015. Epub 2010 Nov 4.

34.

Stromal biology and therapy in pancreatic cancer.

Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA.

Gut. 2011 Jun;60(6):861-8. doi: 10.1136/gut.2010.226092. Epub 2010 Oct 21. Review.

PMID:
20966025
35.

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA.

Science. 2009 Jun 12;324(5933):1457-61. doi: 10.1126/science.1171362. Epub 2009 May 21.

36.

Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model.

Bertout JA, Patel SA, Fryer BH, Durham AC, Covello KL, Olive KP, Goldschmidt MH, Simon MC.

Cancer Res. 2009 Apr 1;69(7):3213-20. doi: 10.1158/0008-5472.CAN-08-4223. Epub 2009 Mar 17.

37.

K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses.

Cook N, Olive KP, Frese K, Tuveson DA.

Methods Enzymol. 2008;439:73-85. doi: 10.1016/S0076-6879(07)00406-5.

PMID:
18374157
38.

The use of targeted mouse models for preclinical testing of novel cancer therapeutics.

Olive KP, Tuveson DA.

Clin Cancer Res. 2006 Sep 15;12(18):5277-87. Review.

39.

Mouse models of human non-small-cell lung cancer: raising the bar.

Kim CF, Jackson EL, Kirsch DG, Grimm J, Shaw AT, Lane K, Kissil J, Olive KP, Sweet-Cordero A, Weissleder R, Jacks T.

Cold Spring Harb Symp Quant Biol. 2005;70:241-50. Review.

PMID:
16869760
40.

The differential effects of mutant p53 alleles on advanced murine lung cancer.

Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T.

Cancer Res. 2005 Nov 15;65(22):10280-8.

41.

Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development.

Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A.

Cancer Res. 2005 Sep 15;65(18):8166-73.

42.

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T.

Cell. 2004 Dec 17;119(6):847-60.

43.

The use of an indwelling peritoneal catheter in the treatment of chronic renal failure.

Petrie JJ, Jones EO, Hartley LC, Olive KP, Clunie GJ.

Med J Aust. 1976 Jul 24;2(4):119-22.

PMID:
979823

Supplemental Content

Loading ...
Support Center